Non-Discrimination Notice

ATLAS 3003

ATLAS 3003– A study of investigational drug with radiation therapy for prostate cancer

Some Requirements:

1. Male age 18 or over
2. Scheduled for radiation therapy for prostate cancer
3. Meet PSA criteria

Sponsored by: Janssen
Length of Study: 2 years
Enrollment: Open

Please contact one of our Clinical Research Coordinators today to find out more information if you are interested in this trial.

Research Department (315) 478-4185, option 7

Our Investigator for this study is Christopher Pieczonka, M.D.